T1D2
MCID: TYP028
MIFTS: 49

Type 1 Diabetes Mellitus 2 (T1D2)

Categories: Endocrine diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Type 1 Diabetes Mellitus 2

MalaCards integrated aliases for Type 1 Diabetes Mellitus 2:

Name: Type 1 Diabetes Mellitus 2 57 12 15
Diabetes Mellitus, Insulin-Dependent, 2 57 72 29 13 6 70
Diabetes Mellitus, Noninsulin-Dependent, 1 57 29 39 70
Iddm2 57 12 72
Diabetes Mellitus, Noninsulin-Dependent 1 57 13
Insulin-Dependent Diabetes Mellitus 2 57 12
Niddm1 57 72
Diabetes Mellitus, Noninsulin-Dependent, 1; Niddm1 57
Diabetes Mellitus, Insulin-Dependent, 2; Iddm2 57
Diabetes Mellitus, Insulin-Dependent, Type 2 39
Diabetes Mellitus, Non-Insulin-Dependent, 1 72
Noninsulin-Dependent Diabetes Mellitus 1 57
Diabetes Mellitus, Non-Insulin-Dependent 70
Type 2 Diabetes Mellitus 1 57
T1d2 57
T2d1 57

Characteristics:

OMIM®:

57 (Updated 05-Apr-2021)
Inheritance:
autosomal dominant form (? 11q)


HPO:

31
type 1 diabetes mellitus 2:
Inheritance autosomal dominant inheritance


Classifications:



External Ids:

Disease Ontology 12 DOID:0110741
OMIM® 57 125852 601283
ICD10 32 E10
SNOMED-CT via HPO 68 263681008 46635009 73211009
UMLS 70 C0011860 C1832544 C1852092

Summaries for Type 1 Diabetes Mellitus 2

UniProtKB/Swiss-Prot : 72 Diabetes mellitus, insulin-dependent, 2: A multifactorial disorder of glucose homeostasis that is characterized by susceptibility to ketoacidosis in the absence of insulin therapy. Clinical features are polydipsia, polyphagia and polyuria which result from hyperglycemia-induced osmotic diuresis and secondary thirst. These derangements result in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.
Diabetes mellitus, non-insulin-dependent, 1: A multifactorial disorder of glucose homeostasis caused by a lack of sensitivity to the body's own insulin. Affected individuals usually have an obese body habitus and manifestations of a metabolic syndrome characterized by diabetes, insulin resistance, hypertension and hypertriglyceridemia. The disease results in long-term complications that affect the eyes, kidneys, nerves, and blood vessels.

MalaCards based summary : Type 1 Diabetes Mellitus 2, also known as diabetes mellitus, insulin-dependent, 2, is related to alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity and type 1 diabetes mellitus 4. An important gene associated with Type 1 Diabetes Mellitus 2 is INS (Insulin), and among its related pathways/superpathways are NF-kappaB Signaling and Allograft rejection. The drugs Metformin and Glimepiride have been mentioned in the context of this disorder. Affiliated tissues include bone marrow, bone and liver, and related phenotypes are diabetes mellitus and type i diabetes mellitus

Disease Ontology : 12 A type 1 diabetes mellitus that has material basis in autosomal dominant inheritance of mutation of the INS gene on chromosome 11p15.5.

More information from OMIM: 125852 601283

Related Diseases for Type 1 Diabetes Mellitus 2

Diseases in the Diabetes Mellitus family:

Type 1 Diabetes Mellitus 2 Type 2 Diabetes Mellitus
Type 1 Diabetes Mellitus Type 1 Diabetes Mellitus 3
Type 1 Diabetes Mellitus 4 Type 1 Diabetes Mellitus 5
Type 1 Diabetes Mellitus 7 Type 1 Diabetes Mellitus 8
Type 1 Diabetes Mellitus 11 Type 1 Diabetes Mellitus 13
Type 1 Diabetes Mellitus 12 Type 2 Diabetes Mellitus 2
Type 1 Diabetes Mellitus 15 Type 1 Diabetes Mellitus 6
Type 1 Diabetes Mellitus 10 Type 1 Diabetes Mellitus 17
Type 2 Diabetes Mellitus 3 Diabetes Mellitus, Congenital Autoimmune
Type 1 Diabetes Mellitus 18 Type 2 Diabetes Mellitus 4
Type 1 Diabetes Mellitus 19 Type 1 Diabetes Mellitus 20
Type 1 Diabetes Mellitus 21 Type 1 Diabetes Mellitus 22
Type 1 Diabetes Mellitus 23 Type 1 Diabetes Mellitus 24
Type 2 Diabetes 5 Rare Diabetes Mellitus Type 1
Rare Diabetes Mellitus Type 2 Rare Diabetes Mellitus

Diseases related to Type 1 Diabetes Mellitus 2 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 85)
# Related Disease Score Top Affiliating Genes
1 alpha/beta t-cell lymphopenia with gamma/delta t-cell expansion, severe cytomegalovirus infection, and autoimmunity 30.3 PTPRN PTPN22 INS CTLA4 AIRE
2 type 1 diabetes mellitus 4 30.2 GIMAP5 FGF3
3 thyroiditis 30.1 PTPN22 INS CTLA4 AIRE
4 graves' disease 29.8 PTPN22 HLA-DQB1 HLA-DQA1 CTLA4 AIRE
5 type 1 diabetes mellitus 29.7 TNFRSF25 PTPRN PTPN22 INS IGF2 HLA-DQB1
6 autoimmune disease 29.7 PTPRN PTPN22 INS HLA-DQB1 HLA-DQA1 CTLA4
7 type 2 diabetes mellitus 29.3 PTPRN INS IGF2 HLA-DQB1 HLA-DQA1 G6PC2
8 diabetes mellitus 28.5 TNFRSF25 PTPRN PTPN22 INS-IGF2 INS IGF2
9 hirata disease 10.4 TNFRSF10A INS
10 diabetes mellitus, permanent neonatal, 4 10.4 INS-IGF2 INS
11 silver-russell syndrome 3 10.4 INS-IGF2 IGF2
12 anca-associated vasculitis 10.4 PTPN22 CTLA4
13 adie pupil 10.3 TOR1A TNFRSF25
14 hypoglycemic coma 10.3 INS IGF2
15 potter's syndrome 10.3 INS IGF2
16 adult syndrome 10.3 INS-IGF2 INS IGF2
17 hyperproinsulinemia 10.3 INS-IGF2 INS
18 hyperandrogenism 10.3 INS IGF2 CAPN10
19 adrenal gland disease 10.3 INS IGF2 AIRE
20 achalasia, familial esophageal 10.3 HLA-DQB1 HLA-DQA1
21 adult-onset myasthenia gravis 10.3 HLA-DQA1 CTLA4
22 selective igg deficiency disease 10.3 TOR1A TNFRSF25
23 primary adrenal insufficiency 10.3 HLA-DQB1 HLA-DQA1
24 amelogenesis imperfecta, type ib 10.3 TNFRSF25 TNFRSF10A
25 central nervous system vasculitis 10.3 TNFRSF10A PTPN22 CTLA4
26 type 1 diabetes mellitus 13 10.3 PTPRN CAPN10
27 type 1 diabetes mellitus 19 10.3 TRAFD1 HHIPL1
28 hypoadrenocorticism, familial 10.3 PTPN22 CTLA4 AIRE
29 hair disease 10.3 INS CTLA4 AIRE
30 wissler-fanconi syndrome 10.3 PTPRN AIRE
31 turner syndrome 10.3 PTPN22 INS IGF2
32 vitiligo-associated multiple autoimmune disease susceptibility 1 10.3 PTPN22 CTLA4 AIRE
33 type 1 diabetes mellitus 24 10.3 GIMAP5 G6PC2
34 autoimmune hepatitis type 1 10.3 HLA-DQB1 HLA-DQA1
35 myasthenia gravis 10.2 HLA-DQB1 CTLA4 AIRE
36 temporal arteritis 10.2 TNFRSF10A PTPN22 CTLA4
37 type 1 diabetes mellitus 18 10.2 TRAFD1 TNFRSF25 PTPN22
38 podoconiosis 10.2 HLA-DQB1 HLA-DQA1
39 autoimmune polyendocrine syndrome, type ii 10.2 TNFRSF25 PTPN22 INS AIRE
40 permanent neonatal diabetes mellitus 10.2 INS-IGF2 INS G6PC2
41 hypoparathyroidism 10.2 INS CTLA4 AIRE
42 immunoglobulin alpha deficiency 10.2 TOR1A TNFRSF25 HLA-DQB1
43 parathyroid gland disease 10.2 INS FGF3 AIRE
44 oligoarticular juvenile idiopathic arthritis 10.2 PTPN22 HLA-DQB1 HLA-DQA1
45 autoimmune hepatitis 10.2 HLA-DQB1 CTLA4 AIRE
46 shrimp allergy 10.2 HLA-DQB1 HLA-DQA1
47 pemphigoid gestationis 10.2 TNFRSF25 TNFRSF10A
48 immunodeficiency 31c 10.2 TNFRSF25 TNFRSF10A PTPN22 AIRE
49 focal epithelial hyperplasia 10.2 TNFRSF10A HLA-DQB1 HLA-DQA1
50 latent autoimmune diabetes in adults 10.2 PTPN22 INS HLA-DQB1 CTLA4

Graphical network of the top 20 diseases related to Type 1 Diabetes Mellitus 2:



Diseases related to Type 1 Diabetes Mellitus 2

Symptoms & Phenotypes for Type 1 Diabetes Mellitus 2

Human phenotypes related to Type 1 Diabetes Mellitus 2:

31
# Description HPO Frequency HPO Source Accession
1 diabetes mellitus 31 HP:0000819
2 type i diabetes mellitus 31 HP:0100651

Symptoms via clinical synopsis from OMIM®:

57 (Updated 05-Apr-2021)
Endo:
insulin-dependent diabetes mellitus

Clinical features from OMIM®:

125852 601283 (Updated 05-Apr-2021)

MGI Mouse Phenotypes related to Type 1 Diabetes Mellitus 2:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 endocrine/exocrine gland MP:0005379 10.1 AIRE CAPN10 CTLA4 G6PC2 HLA-DQA1 HLA-DQB1
2 hematopoietic system MP:0005397 10.07 AIRE CAPN10 CTLA4 FGF3 G6PC2 HLA-DQA1
3 immune system MP:0005387 10.03 AIRE CAPN10 CTLA4 FGF3 G6PC2 HLA-DQA1
4 liver/biliary system MP:0005370 9.5 AIRE CAPN10 CTLA4 HLA-DQB1 IGF2 INS
5 mortality/aging MP:0010768 9.44 AIRE CTLA4 FGF3 HHIPL1 HLA-DQB1 IGF2

Drugs & Therapeutics for Type 1 Diabetes Mellitus 2

Drugs for Type 1 Diabetes Mellitus 2 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 69)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Metformin Approved Phase 4 657-24-9 4091 14219
2
Glimepiride Approved Phase 4 93479-97-1 3476
3
Vildagliptin Approved, Investigational Phase 4 274901-16-5 6918537
4
Saxagliptin Approved Phase 4 361442-04-8 11243969
5
Liraglutide Approved Phase 4 204656-20-2 44147092
6
Glyburide Approved Phase 4 10238-21-8 3488
7 Anti-Arrhythmia Agents Phase 4
8 Immunosuppressive Agents Phase 4
9 Immunologic Factors Phase 4
10 Hypoglycemic Agents Phase 4
11 Dipeptidyl-Peptidase IV Inhibitors Phase 4
12
protease inhibitors Phase 4
13 HIV Protease Inhibitors Phase 4
14 Hormone Antagonists Phase 4
15 Incretins Phase 4
16 Hormones Phase 4
17 Sitagliptin Phosphate Phase 4
18
Insulin glargine Approved Phase 3 160337-95-1
19
Zinc Approved, Investigational Phase 3 7440-66-6 32051
20
Exenatide Approved, Investigational Phase 3 141758-74-9 15991534
21
Glucagon Approved Phase 2, Phase 3 16941-32-5
22
Inositol Approved, Investigational, Withdrawn Phase 3 87-89-8
23
Rosiglitazone Approved, Investigational Phase 3 122320-73-4 77999
24
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
25
2,4-thiazolidinedione Investigational Phase 3 2295-31-0
26
Voglibose Investigational Phase 3 83480-29-9 444020
27 Insulin, Globin Zinc Phase 3
28 insulin Phase 3
29 Vitamins Phase 3
30 Omega 3 Fatty Acid Phase 3
31 Pharmaceutical Solutions Phase 3
32 Olive Phase 3
33 Eicosapentaenoic acid ethyl ester Phase 3
34 Anti-Obesity Agents Phase 3
35 Glucagon-Like Peptide 1 Phase 2, Phase 3
36 Vitamin B9 Phase 3
37 Nutrients Phase 3
38 Glycoside Hydrolase Inhibitors Phase 3
39 Micronutrients Phase 3
40 Trace Elements Phase 3
41 Vitamin B Complex Phase 3
42 Folate Phase 3
43 Cardiac Glycosides Phase 3
44 Zinc Supplement Phase 2, Phase 3
45 2-(3-(4-ethoxybenzyl)-4-chlorophenyl)-6-hydroxymethyltetrahydro-2H-pyran-3,4,... Phase 3
46 Sodium-Glucose Transporter 2 Inhibitors Phase 3
47
Acetylcholine Approved, Investigational Phase 2 51-84-3 187
48
Pramlintide Approved, Investigational Phase 2 151126-32-8
49
Mannitol Approved, Investigational Phase 2 69-65-8 6251 453
50
Vitamin C Approved, Nutraceutical Phase 2 50-81-7 5785 54670067

Interventional clinical trials:

(show top 50) (show all 60)
# Name Status NCT ID Phase Drugs
1 Effects of Vildagliptine and Glimepiride on Glycemic Variability and Cardiovascular Parameters in Patients With Type 2 Diabetes by CGMS Completed NCT01812122 Phase 4 Glimepiride;Vildagliptin
2 SCARF: Saxagliptin on CArdiac StRucture and Function Completed NCT02481479 Phase 4 Saxagliptin;Saxagliptin;saxagliptin
3 To Evaluate the Effect of Liraglutide on Ambulatory Blood Pressure-A Pilot Study Completed NCT02299388 Phase 4 Liraglutide or Placebo
4 A Research Study to Assess the Mechanism By Which Glucovance, Metformin, and Glyburide Work To Control Glucose Levels In Patients With Type 2 Diabetes Completed NCT00035568 Phase 4 Glucovance (metformin HCl/glyburide);or Metformin HCl alone;or Glyburide alone.
5 A Multicenter, Single Arm, Cohort Study to Evaluate the Efficacy and Safety of Saxagliptin 5mg, Once Daily for 24 Weeks, in Patients With Type 2 Diabetes Mellitus Completed NCT01608724 Phase 4 Saxagliptin
6 Making Ramadhan Fasting a Safer Experience With Technology Study Completed NCT02189135 Phase 4
7 Open-label, Non Placebo-Controlled Study To Verify the Effect of Sitagliptin In Adult Patients With Type 2 Diabetes and Inadequate Glycemic Control Terminated NCT00832624 Phase 4 sitagliptin
8 Diabetes Prevention Program Completed NCT00004992 Phase 3 Metformin;Placebo
9 A Multicenter, International Randomized, 2x2 Factorial Design Study to Evaluate the Effects of Lantus (Insulin Glargine) Versus Standard Care, and of Omega-3 Fatty Acids Versus Placebo, in Reducing Cardiovascular Morbidity and Mortality in High Risk People With Impaired Fasting Glucose (IFG), Impaired Glucose Tolerance (IGT) or Early Type 2 Diabetes Mellitus: The ORIGIN Trial (Outcome Reduction With Initial Glargine Intervention) Completed NCT00069784 Phase 3 insulin glargine (HOE901);omega-3 polyunsaturated fatty acids (PUFA);placebo
10 A Double-Blind, Placebo-Controlled, Parallel Group Comparison Study to Evaluate the Role of the Addition of Amaryl to NIDDM Patients Not Responding to Maximum Dose Metformin and Thiazolidinedione Therapy Completed NCT00044447 Phase 3 Glimepiride
11 A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Treated With a Sulfonylurea Alone Completed NCT00039026 Phase 3 AC2993;AC2993;Placebo;Placebo
12 A Phase 3, Randomized, Triple-Blind, Parallel-Group, Long-Term, Placebo-Controlled, Multicenter Study to Examine the Effect on Glucose Control (HbA1c) of AC2993 Given Twice Daily in Subjects With Type 2 Diabetes Mellitus Treated With Metformin and a Sulfonylurea Completed NCT00035984 Phase 3 AC2993;AC2993;Placebo;Placebo
13 Sitagliptin (MK0431) Phase III Double-blind Comparative Study - Type 2 Diabetes Mellitus - Completed NCT00411554 Phase 3 sitagliptin phosphate;Comparator: voglibose
14 A Research Study to Determine the Safety and Efficacy of Glucovance Compared to Metformin and Glyburide in Children and Adolescents With Type 2 Diabetes. Completed NCT00035542 Phase 3 Glucovance (metformin HCl/glyburide);metformin HCl;glyburide
15 Does Zinc Supplementation Reduce the Extent of Oxidative Stress Damage in Diabetics? A Randomised Placebo-controlled Study. Completed NCT01309620 Phase 2, Phase 3
16 Assessment of Insulin Sensitivity and β Cell Function by Clamps Studies After Stem Cell Transplantation in T2DM Completed NCT02662400 Phase 2, Phase 3
17 Dapagliflozin Effect on Cardiovascular Events A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Effect of Dapagliflozin 10 mg Once Daily on the Incidence of Cardiovascular Death, Myocardial Infarction or Ischemic Stroke in Patients With Type 2 Diabetes Completed NCT01730534 Phase 3 Dapagliflozin 10 mg;Placebo tablet
18 A Double Blind, Cross Over, Placebo Controlled, Multiple-dose Study to Evaluate the Effects of LAF237 on Gastric Emptying, Gastric Volume and Satiety in Patients With Type 2 Diabetes. Completed NCT00952991 Phase 3 LAF237 = vildagliptin
19 A Multicenter, Randomized, Open-label Study to Assess the Efficacy and Safety of Sitagliptin Added to the Regimen of Patients With T2 DM With Inadequate Glycemic Control on Metformin Completed NCT00875394 Phase 3 sitagliptin phosphate;Comparator: metformin;Comparator: metformin;Comparator: Antidiabetic Standard of Care
20 A Phase III, Randomized, Placebo-controlled, Double-blind Clinical Trial and Subsequent Open-label, Extension Clinical Trial to Study the Efficacy and Safety of Addition of Sitagliptin in Japanese Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Diet/Exercise Therapy and Voglibose Monotherapy Completed NCT00837577 Phase 3 Comparator: Placebo;Sitagliptin;Voglibose
21 A Double-blind, Placebo Controlled, Parallel Group Comparative Study to Evaluate the Efficacy and Safety of BRL 49653C With Concurrent Sulphonylurea Therapy, When Administered to Patients With Non-insulin Dependent Diabetes Mellitus. Completed NCT01706211 Phase 3 BRL 49653C;Placebo
22 A Phase III, Multicenter, Double-Blind, Randomized Study to Evaluate the Safety and Efficacy of the Addition of Sitagliptin Compared With the Addition of Glimepiride in Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Control on Metformin Completed NCT00701090 Phase 3 sitagliptin;Comparator: glimepiride;open-label metformin
23 Multicenter, Open, Pragmatic, Randomized Trial Comparing the Efficacy of 3 Different Lifestyle Interventions After Addition of Sitagliptin to Patients With Type 2 Diabetes Mellitus Who Have Inadequate Glycemic Control on Metformin Therapy Completed NCT00545584 Phase 3 sitagliptin phosphate
24 An Exploratory Study of the Effects of Oral Vitamin C Administration on Insulin Sensitivity and Vascular Reactivity in Subjects With Type 2 Diabetes Completed NCT00001870 Phase 2 Acetylcholine
25 Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide Completed NCT00044707 Phase 2 Pramlintide acetate
26 A Phase 2, Randomized, Triple-Blind, Placebo-Controlled, Short-Term, Dose-Response Study to Examine the Effect on Glucose Control and Safety and Tolerability of AC2993 Given Two Times a Day in Subjects With Type 2 Diabetes Mellitus Completed NCT00044694 Phase 2 Placebo 0.01 mL;Placebo 0.02 mL;Placebo 0.03 mL;Placebo 0.04 mL;AC2993 2.5 mcg;AC2993 5.0 mcg;AC2993 7.5 mcg;AC2993 10.0 mcg
27 An Evaluation of an Oral Antidiabetic Agent for the Treatment of Type 2 Diabetes Completed NCT00065312 Phase 2 naveglitazar
28 A Randomized, Double-blind, Placebo-controlled, Rising-dose, Multicenter Study to Evaluate the Efficacy and Safety of 90 Days of 300 or 600 mg Daily Subcutaneous Injections of INGAP Peptide in Insulin-using Type 2 Diabetes Mellitus Patients Completed NCT00071422 Phase 2 INGAP-Peptide;INGAP-Peptide;placebo
29 Effect of Gelofusine on 111In-DTPA-AHX-Lys40-Exendin 4 Uptake in the Kidney Completed NCT02541734 Phase 1, Phase 2 Gelofusine;Placebo
30 Tissue Distribution of F18-FDG Labeled Autologous Bone Marrow Derived Stem Cells in Patients With Type2 Diabetes Mellitus Completed NCT02585505 Phase 1, Phase 2
31 Phase II Study on Sitagliptin -Assessment of Glucose-lowering Effects Completed NCT00758069 Phase 2 sitagliptin phosphate;Comparator: Placebo;Comparator: Sitagliptin
32 Randomized Clinical Trial With Broccoli Sprout Extract to Patients With Type 2 Diabetes Active, not recruiting NCT02801448 Phase 2 sulforaphane;Placebo
33 An Open-label, Single and Repeat Single Ascending Dose Escalation Study to Compare the Pharmacokinetics of Metformin Eicosapentaenoate With Metformin Hydrochloride and Icosapent Ethyl Following Oral Administration to Healthy Volunteers Unknown status NCT02113163 Phase 1 Metformin Eicosapentaenoate;Metformin HCl and Vascepa
34 NNC 90-1170 Mechanism of Action: A Double-Blind, Randomized, Single-Center, Placebo-Controlled, Crossover Study to Examine Beta-Cell Responsiveness to Graded Glucose Infusion in Subjects With Type 2 Diabetes Completed NCT00013910 Phase 1 NNC 90-1170
35 Randomized, Placebo-Controlled, Single Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of BMS-816336 in Healthy Male Subjects Completed NCT00979368 Phase 1 BMS-816336;BMS-816336;BMS-816336;BMS-816336;BMS-816336;Placebo
36 Placebo-Controlled, Ascending Single-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of BMS-820132 in Subjects With Type 2 Diabetes on Background Therapy of Metformin Completed NCT01105429 Phase 1 BMS-820132;BMS-820132;BMS-820132;BMS-820132;BMS-820132;BMS-820132;BMS-820132;BMS-820132;BMS-820132;Placebo;Placebo
37 A Single Dose Clinical Trial to Study the Safety, Tolerability, Pharmacodynamics, and Pharmacokinetics of MK-1006 in Japanese Subject With Type 2 Diabetes Completed NCT00791661 Phase 1 MK-1006;Placebo
38 A Multiple Dose Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of MK-0941 in Japanese Patients With Type 2 Diabetes Completed NCT00754130 Phase 1 Placebo;MK-0941
39 An Open-Label, Single- & Multiple-Dose Study to Investigate the Pharmacokinetics of Sitagliptin 100 mg in Healthy Chinese Adult Subjects Completed NCT00642798 Phase 1 sitagliptin phosphate
40 Identification and Therapy Efficacy of Type 2 Diabetes in Hispanic Patients Unknown status NCT00004572
41 The Efficacy of a Nurse-led Reminder Program on Therapy Adherence, Clinical Outcomes and Trust in Nurses in Diabetic Patients. Unknown status NCT02196272
42 Effect of Modified Laparoscopic Roux-en-Y Gastric Bypass Surgery on Type 2 Diabetics With Lower Body Mass Index in China Unknown status NCT02091323
43 Acute Glycemic Effects of a Very Low Fat Diet in Type 2 Diabetes Completed NCT00006432
44 A Double Blind Randomized Control Trial to Study the Effect of Vitamin D Supplementation on Peripheral Insulin Sensitivity in Centrally Obese Men Completed NCT00347542 Vitamin D
45 A Pilot Study to Evaluate the Effect of Vitamin D Supplementation on Insulin Secretion and Peripheral Insulin Sensitivity Completed NCT00320853 Vitamin D
46 Effects of Exercise Training on Left Ventricular Function in Type 2 Diabetic Patients Post Coronary Artery Bypass Graft Completed NCT00172536
47 Effectiveness and Cost-effectiveness of the Diabetes Integrated Care Breakthrough Collaborative to Improve Diabetes Care, Its Health Outcomes and Economic Costs Completed NCT00160017
48 Heavy Metals, Obesity and Cardiovascular Risk - Ancillary to Look AHEAD Completed NCT00031213
49 Education and Group Support for Diabetic Hispanics Completed NCT00004983
50 Evaluation of Advanced Glycation End-products (AGE) and the Erectile Dysfunction (DE) in Diabetic Patients Completed NCT02770235

Search NIH Clinical Center for Type 1 Diabetes Mellitus 2

Inferred drug relations via UMLS 70 / NDF-RT 51 :


Acarbose
Acetohexamide
albiglutide
alogliptin
alogliptin benzoate
canagliflozin
Chlorpropamide
dulaglutide
empagliflozin
exenatide
glimepiride
Glipizide
Glyburide
Insulin
insulin beef, isophane
insulin beef-pork, isophane
insulin degludec
Insulin Glargine
insulin human, isophane
Insulin Lispro
insulin pork, isophane
Insulin, Aspart Protamine, Human
Insulin, Aspart, Human
Insulin, Glulisine, Human
Insulin, Prompt Zinc, Beef
Insulin, Prompt Zinc, Beef-Pork
Insulin, Prompt Zinc, Pork
Insulin, Protamine Lispro, Human
insulin, protamine zinc, beef
Insulin, Protamine Zinc, Beef-Pork
Insulin, Protamine Zinc, Pork
Insulin, Regular, Beef
insulin, regular, beef-pork
Insulin, Regular, Pork
Insulin, Zinc, Human
Insulin, Zinc, Pork
INSULIN,DETEMIR,HUMAN
INSULIN,REGULAR,HUMAN BUFFERED
Lente Insulin, Beef
Lente Insulin, Beef-Pork
Metformin
Metformin hydrochloride
miglitol
nateglinide
pioglitazone
Pioglitazone hydrochloride
Pramlintide
Regular Insulin, Human
repaglinide
rosiglitazone
Rosiglitazone maleate
sitagliptin
sitagliptin phosphate
Tolazamide
Tolbutamide
Tolbutamide sodium
troglitazone
Ultralente Insulin, Beef
Ultralente Insulin, Beef-Pork
Ultralente Insulin, Human

Genetic Tests for Type 1 Diabetes Mellitus 2

Genetic tests related to Type 1 Diabetes Mellitus 2:

# Genetic test Affiliating Genes
1 Diabetes Mellitus, Insulin-Dependent, 2 29 INS
2 Diabetes Mellitus, Noninsulin-Dependent, 1 29 CAPN10

Anatomical Context for Type 1 Diabetes Mellitus 2

MalaCards organs/tissues related to Type 1 Diabetes Mellitus 2:

40
Bone Marrow, Bone, Liver, Thymus, Pancreas, Thyroid

Publications for Type 1 Diabetes Mellitus 2

Articles related to Type 1 Diabetes Mellitus 2:

(show all 37)
# Title Authors PMID Year
1
Mutations in the insulin gene can cause MODY and autoantibody-negative type 1 diabetes. 6 57
18192540 2008
2
Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. 57
19430480 2009
3
Meta-analysis of genome-wide association study data identifies additional type 1 diabetes risk loci. 57
18978792 2008
4
Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. 57
17554300 2007
5
Unusual DNA structure of the diabetes susceptibility locus IDDM2 and its effect on transcription by the insulin promoter factor Pur-1/MAZ. 57
11070077 2000
6
The insulin gene VNTR, type 2 diabetes and birth weight. 57
10080175 1999
7
Weighing in on diabetes risk. 57
9662384 1998
8
Association of the INS VNTR with size at birth. ALSPAC Study Team. Avon Longitudinal Study of Pregnancy and Childhood. 57
9590300 1998
9
Type II diabetes, essential hypertension, and obesity as "syndromes of impaired genetic homeostasis": the "thrifty genotype" hypothesis enters the 21st century. 57
9894356 1998
10
Insulin VNTR allele-specific effect in type 1 diabetes depends on identity of untransmitted paternal allele. The IMDIAB Group. 57
9354805 1997
11
Insulin gene region contributes to genetic susceptibility to, but may not to low incidence of, insulin-dependent diabetes mellitus in Japanese. 57
9144439 1997
12
The insulin gene is transcribed in the human thymus and transcription levels correlated with allelic variation at the INS VNTR-IDDM2 susceptibility locus for type 1 diabetes. 57
9054945 1997
13
Insulin expression in human thymus is modulated by INS VNTR alleles at the IDDM2 locus. 57
9054944 1997
14
Imprinted and genotype-specific expression of genes at the IDDM2 locus in pancreas and leucocytes. 57
8816977 1996
15
IDDM2-VNTR-encoded susceptibility to type 1 diabetes: dominant protection and parental transmission of alleles of the insulin gene-linked minisatellite locus. 57
8816980 1996
16
Human type 1 diabetes and the insulin gene: principles of mapping polygenes. 57
8982458 1996
17
Two-locus maximum lod score analysis of a multifactorial trait: joint consideration of IDDM2 and IDDM4 with IDDM1 in type 1 diabetes. 57
7573054 1995
18
The minisatellite in the diabetes susceptibility locus IDDM2 regulates insulin transcription. 57
7773292 1995
19
Susceptibility to human type 1 diabetes at IDDM2 is determined by tandem repeat variation at the insulin gene minisatellite locus. 57
7773291 1995
20
A genome-wide search for human type 1 diabetes susceptibility genes. 57
8072542 1994
21
Transmission test for linkage disequilibrium: the insulin gene region and insulin-dependent diabetes mellitus (IDDM). 57
8447318 1993
22
Insulin gene region-encoded susceptibility to type 1 diabetes is not restricted to HLA-DR4-positive individuals. 57
1345171 1992
23
Insulin-IGF2 region on chromosome 11p encodes a gene implicated in HLA-DR4-dependent diabetes susceptibility. 57
1944595 1991
24
Fetal and infant growth and impaired glucose tolerance at age 64. 57
1954451 1991
25
Linkage strategies for genetically complex traits. I. Multilocus models. 57
2301392 1990
26
HLA and insulin gene associations with IDDM. 57
2567257 1989
27
A polymorphic locus near the human insulin gene is associated with insulin-dependent diabetes mellitus. 57
6363172 1984
28
Polymorphic DNA region adjacent to the 5' end of the human insulin gene. 57
6272317 1981
29
Diabetes mellitus: a "thrifty" genotype rendered detrimental by "progress"? 57
13937884 1962
30
Increased Glucose Availability Attenuates Myocardial Ketone Body Utilization. 61
32750298 2020
31
Clinical features and treatment responses in pediatric lymphocytic and collagenous colitis. 61
23820404 2013
32
Diabetes distress in Type 1 diabetes--a new measurement fit for purpose. 61
23701311 2013
33
Significantly association of diabetes mellitus with CTLA-4 gene polymorphisms based on a meta-analysis of epidemiological evidence in Asians and non-Asians. 61
24085454 2013
34
Celiac disease and autoimmune thyroid disease. 61
18056028 2007
35
[Helicobacter pylori infection and its metabolic consequences in children and adolescents with type 1 diabetes mellitus]. 61
17625277 2007
36
[Role of fibroblasts in the development of diabetes mellitus and its complications]. 61
31627552 2005
37
[Cardiovascular autonomic neuropathy and nephropathy in patients with type-1 diabetes mellitus]. 61
15518324 2004

Variations for Type 1 Diabetes Mellitus 2

ClinVar genetic disease variations for Type 1 Diabetes Mellitus 2:

6
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 INS-IGF2 , INS NM_000207.3(INS):c.94G>A (p.Gly32Ser) SNV Pathogenic 21122 rs80356664 GRCh37: 11:2182108-2182108
GRCh38: 11:2160878-2160878
2 INS-IGF2 , INS NM_000207.3(INS):c.163C>T (p.Arg55Cys) SNV Pathogenic 13392 rs121908261 GRCh37: 11:2182039-2182039
GRCh38: 11:2160809-2160809

UniProtKB/Swiss-Prot genetic disease variations for Type 1 Diabetes Mellitus 2:

72
# Symbol AA change Variation ID SNP ID
1 INS p.Arg55Cys VAR_063732 rs121908261

Expression for Type 1 Diabetes Mellitus 2

Search GEO for disease gene expression data for Type 1 Diabetes Mellitus 2.

Pathways for Type 1 Diabetes Mellitus 2

GO Terms for Type 1 Diabetes Mellitus 2

Cellular components related to Type 1 Diabetes Mellitus 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 MHC class II protein complex GO:0042613 8.96 HLA-DQB1 HLA-DQA1
2 transport vesicle membrane GO:0030658 8.8 PTPRN HLA-DQB1 HLA-DQA1

Biological processes related to Type 1 Diabetes Mellitus 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of glycogen biosynthetic process GO:0045725 9.26 INS IGF2
2 positive regulation of protein kinase B signaling GO:0051897 9.26 MAZ INS IGF2 FGF3
3 antigen processing and presentation of peptide or polysaccharide antigen via MHC class II GO:0002504 9.16 HLA-DQB1 HLA-DQA1
4 T cell receptor signaling pathway GO:0050852 8.92 PTPN22 HLA-DQB1 HLA-DQA1 CTLA4

Molecular functions related to Type 1 Diabetes Mellitus 2 according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 9.33 INS-IGF2 INS IGF2
2 insulin-like growth factor receptor binding GO:0005159 8.96 INS IGF2
3 MHC class II receptor activity GO:0032395 8.62 HLA-DQB1 HLA-DQA1

Sources for Type 1 Diabetes Mellitus 2

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....